Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Recruitment Status: Authorised-recruitment may be ongoing or finished"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Medical+Condition%3A+Covid19%22&type=Subject&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22
/vufind/Search/Results?lookfor=%22Medical+Condition%3A+Covid19%22&type=Subject&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22
Search /vufind/Search2/Results?lookfor=%22Medical+Condition%3A+Covid19%22&type=Subject&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22
PubPharm (316)
1
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase IIItrial. (REPAVID-22)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase IIItrial. (REPAVID-22)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Evaluation of the efficacy and safety of a polyclonal equine fragments immunotherapy (FBR-002) in participants with COVID-19 requiring supplemental oxygen in hospital and at risk of severe outcome : A phase IIb randomized, placebo-controlled, double-blind study, to evaluate the efficacy and safety of FBR-002 in participants hospitalized with COVID-19 in need of supplemental oxygen and at risk of severe outcome
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
A phase I/III study to assess pre-exposure prophylaxis of AZD5156 in immunocompromised individuals : A Phase I/III Randomized, Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment - SUPERNOVA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Evaluation of the efficacy and safety of a polyclonal equine fragments immunotherapy (FBR-002) in participants with COVID-19 requiring supplemental oxygen in hospital and at risk of severe outcome : A phase IIb randomized, placebo-controlled, double-blind study, to evaluate the efficacy and safety of FBR-002 in participants hospitalized with COVID-19 in need of supplemental oxygen and at risk of severe outcome
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A phase I/III study to assess pre-exposure prophylaxis of AZD5156 in immunocompromised individuals : A Phase I/III Randomized, Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment - SUPERNOVA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
clinical trial to evaluate the tolerability, efficacy and safety ofAesculus Hippocastanum L seed extract in COVID-19 patients withmild pneumonia : An open-label, randomized, parallel-controlled, phase II-IIIclinical trial to evaluate the tolerability, efficacy and safety ofAesculus Hippocastanum L seed extract in COVID-19 patients withmild pneumonia - Aesculus Hippocastanum L seed extract in Covid-19 patients
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
clinical trial to evaluate the tolerability, efficacy and safety ofAesculus Hippocastanum L seed extract in COVID-19 patients withmild pneumonia : An open-label, randomized, parallel-controlled, phase II-IIIclinical trial to evaluate the tolerability, efficacy and safety ofAesculus Hippocastanum L seed extract in COVID-19 patients withmild pneumonia - Aesculus Hippocastanum L seed extract in Covid-19 patients
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) : An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) - Kinarus COVID-19 Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) : An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) - Kinarus COVID-19 Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[32]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Recruitment Status: Authorised-recruitment may be ongoing or finished
Medienart
316
Aufsätze
316
E-Artikel
316
E-Ressourcen
Zeitschriftentitel
316
WHO International Clinical Trials Registry Plat...
Thema
316
610
Recruitment Status: Authorised-recruitment may ...
316
Study Type: Interventional
142
Phase: Phase 2
130
Phase: Phase 3
38
Medical Condition: COVID-19;Therapeutic area: D...
38
Phase: Phase 4
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 MedDRA version: 23....
12
Medical Condition: COVID-19 infection MedDRA ve...
10
Medical Condition: COVID-19 MedDRA version: 23....
10
Medical Condition: COVID-19;Therapeutic area: D...
8
Medical Condition: COVID-19 infection MedDRA ve...
6
Medical Condition: COVID-19 (Coronavirus Diseas...
6
Medical Condition: COVID-19;Therapeutic area: B...
6
Phase: Phase 1
4
Medical Condition: COVID 19 MedDRA version: 20....
4
Medical Condition: COVID-19 MedDRA version: 20....
4
Medical Condition: COVID-19 MedDRA version: 23....
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
6
2023
36
2022
136
2021
138
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
306
Englisch
6
Unbestimmt
2
Deutsch
2
Polnisch
Haven't found what you're looking for?
Wird geladen...